Business
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 – 20, 2023. Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy. Oral presentation details: Initial biomarker and clinical findings from the CANaspire Canavan disease gene therapy trial: Exploration of connections between NAA and disease severityPresenter: Florian Eichler, M.D., director of the leukodystrophy service at Massachusetts General Hospital, Center for Rare Neurological Disease and lead CANaspire investigatorSession date/ time: Saturday, May 20 at 10:15 am – 12:00 pm PTPresentation time: 11:15 am – 11:30 am PTLocation: Concourse Hall 150 & 151, Los Angeles Convention CenterSession title: Gene and cell therapy trials in progressAbstract number: 358 Additional panel details: Accelerated approval for cell and gene therapiesDate & time: Wednesday, May 17 at 9:00 am – 9:45 am PTPanelist: Adora Ndu, Pharm.D., J.D., chief regulatory and interim legal officer of BridgeBioLocation: Room 515 AB, Los Angeles Convention Center Venture capital in the gene and cell therapy spaceDate & time: Friday, May 19 at 8:00 am – 9:45 am PTCo-chair: Eric David, M.D., J.D., CEO of BridgeBio Gene TherapyPanelist: Neil Kumar, Ph.D., founder and CEO of BridgeBioLocation: Concourse Hall 152 & 153, Los Angeles Convention Center Evolution of genetic medicines: Navigating the challenges and synergies among therapeutic modalitiesDate & time: Friday, May 19 at 10:15 am – 12:30 pm PT Panelist: Eric David, M.D., J.D., CEO of BridgeBio Gene TherapyLocation: Room 411, Los Angeles Convention Center Accelerate your drug development program in rare disease with robust natural history data: An evolving spaceSession title: How to design a natural history study that regu...